

Anti-CEACAM5/CEA/CD66e Antibody (Labetuzumab govitecan)

Introduction

Labetuzumab govitecan (IMMU 130) is an anti-CEACAM5/SN-38 antibody-active molecule conjugate (ADC). Labetuzumab govitecan is composed of the antibody Labetuzumab, SN-38, and a pH-sensitive linker. Labetuzumab govitecan can be used in cancer research, such as colorectal cancer.

Product parameters

Alternative Names	IMMU-130, hMN-14-SN38
Target Accession	P06731
Target	CEACAM5 / CEA / CD66e
CAS number	1469876-18-3
Molecular Weight	145.48 kDa
Host	CHO
Reactivity	Human
Conjugation	SN38
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human CEACAM5 / CEA / CD66e HEK293 Cell Line were stained Anti-CEACAM5/CEA/CD66e Antibody (Labetuzumab govitecan) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 1.45 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

